ADVANCE is a clinical trial designed to help change the current first-line HIV treatment (efavirenz/ tenofovir disoproxil fumarate/emtricitabine or EFV/TDF/ FTC) in South Africa and other low- and middle-income countries (LMICs).
WHAT IS THE NEW REGIMEN?
The regimen that is being tested is dolutegravir/tenofovir alafenamide/emtricitabine (DTG/TAF/FTC). There is also a third arm in the trial with DTG/TDF/FTC.
WHAT IS DOLUTEGRAVIR?
DTG is an integrase inhibitor. When HIV infects a cell, it combines its genetic code into the cell’s own code – this is called integration. DTG blocks integration, so HIV can’t make more copies of itself. • DTG is more effective, and has less side effects than EFV. But, it has not been used widely in LMICs.
WHAT IS TENOFOVIR ALAFENAMIDE?
TAF is a nucleotide analogue and new version of tenofovir. It has a much lower dose than TDF (original version of tenofovir).